InvestorsHub Logo
icon url

HappyLibrarian

02/22/22 8:57 AM

#445775 RE: Sir Pumpernickel #445774

Not necessarily. DCVax-L was developed two decades ago. Even an approvavle treatment would surely benefit from some updating that accounts for two decades of research.

Two decades ago there were no iphones and their generic competitors.

Should we have not applied lessons learned to have better phones and still use flip phones?
icon url

Poor Man -

02/22/22 9:03 AM

#445777 RE: Sir Pumpernickel #445774

It’s Pent Up Demand Tuesday.

I’m predicting a lot of orders at the bid.
icon url

dennisdave

02/22/22 9:07 AM

#445779 RE: Sir Pumpernickel #445774

you only quote what you want others to believe


"The next step involves applying lessons learned from the laboratory to improve the vaccine’s efficacy. To that end, the group led by Drs. Liau and Prins launched a trial in 2019 that uses the vaccine in combination with checkpoint inhibitors, based on their laboratory analysis of how tumors in animal models were able to overcome the immunotherapy"



icon url

muee88

02/22/22 12:02 PM

#445850 RE: Sir Pumpernickel #445774

Yes, it failed so badly and it was so completely useless that they decided to start another combo trial using it in 2019.